S-5554-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Elissa Slotkin (D-MI)
What it does
The bill would require group health plans and insurers offering group or individual coverage, including grandfathered plans, to cover genetic counseling, genetic testing, and tumor testing for enrollees with a personal history of ovarian cancer, certain endometrial cancer, or a family history indicating hereditary risk. It would also require coverage of evidence-based early detection and risk-reducing surgeries for people at elevated hereditary risk, starting with plan years one year after enactment. It would reauthorize Johanna's Law awareness efforts at $20 million per year for fiscal years 2027 through 2031, require demonstration project grants, add ovarian cancer to rural health grant programs, and require HHS implementation plans and reports. Other limits apply, including a rule that the least restrictive guideline governs when guidelines conflict.
Who benefits
People with ovarian or endometrial cancer and people with family histories of hereditary cancer syndromes, who would gain coverage for counseling, testing, and risk-reducing care. Relatives of patients who may be identified as at risk. Rural, Tribal, and medically underserved communities targeted by grants and outreach. Genetic counselors, testing laboratories, gynecologic oncologists, community health centers, and rural hospitals that may see more patients or grant funding.
Who is hurt
Group health plans and insurers, including grandfathered plans that were previously exempt, which would face new mandated coverage costs that may be passed on through higher premiums to all enrollees and employers. Self-insured employers would bear added claims costs. Taxpayers would fund the $20 million per year authorization, subject to appropriation. Insurers may have less room to limit coverage because the least restrictive guideline applies. Federal agencies would take on added reporting and implementation work.
Supporters argue
Supporters argue that ovarian cancer is often found late and that genetic testing can guide treatment, prevention, and screening of relatives. They contend a uniform coverage standard, paired with outreach to rural and underserved communities, would reduce gaps in access that the bill's text identifies. They argue the required reports and demonstration projects would build evidence about what works.
Opponents argue
Opponents argue that federal coverage mandates raise premiums for all enrollees and employers, and that applying them to grandfathered plans removes a long-standing exemption. They contend that requiring the least restrictive guideline when guidelines conflict, plus coverage of repeat testing, limits insurers' ability to manage costs. They argue authorized spending and new reporting duties add federal obligations whose benefits remain uncertain.
Constitutional context
Congress regulates health insurance under the Commerce Clause and funds grants under the Spending Clause, and NFIB v. Sebelius (2012) confirms broad power to regulate existing insurance markets while limiting coercive funding conditions on states. The coverage mandate applies to private insurers rather than conditioning state funds, so it raises no clear constitutional problem.
Checks and balances
Congress sets the coverage mandate and funding, the HHS Secretary implements it and reports back to Congress, and Congress controls actual funding through appropriations.
Historical precedent
Congress previously enacted Johanna's Law (2007), which created the ovarian cancer awareness campaign this bill would reauthorize and expand, and the Affordable Care Act mandated preventive-service coverage.